[go: up one dir, main page]

HK1211056A1 - Fusion proteins and methods for treating, preventing or ameliorating pain - Google Patents

Fusion proteins and methods for treating, preventing or ameliorating pain

Info

Publication number
HK1211056A1
HK1211056A1 HK15111817.1A HK15111817A HK1211056A1 HK 1211056 A1 HK1211056 A1 HK 1211056A1 HK 15111817 A HK15111817 A HK 15111817A HK 1211056 A1 HK1211056 A1 HK 1211056A1
Authority
HK
Hong Kong
Prior art keywords
treating
preventing
methods
fusion proteins
ameliorating pain
Prior art date
Application number
HK15111817.1A
Other languages
English (en)
Chinese (zh)
Inventor
Peter James
Keith Foster
John Chaddock
Roger Kei Aoki
Lance Steward
Joseph Francis
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of HK1211056A1 publication Critical patent/HK1211056A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21072—IgA-specific serine endopeptidase (3.4.21.72)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24013—IgA-specific metalloendopeptidase (3.4.24.13)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15111817.1A 2012-08-27 2015-12-01 Fusion proteins and methods for treating, preventing or ameliorating pain HK1211056A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/595,927 US20140056870A1 (en) 2012-08-27 2012-08-27 Fusion proteins
PCT/GB2013/052243 WO2014033441A1 (en) 2012-08-27 2013-08-27 Fusion proteins and methods for treating, preventing or ameliorating pain

Publications (1)

Publication Number Publication Date
HK1211056A1 true HK1211056A1 (en) 2016-05-13

Family

ID=49123869

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15111817.1A HK1211056A1 (en) 2012-08-27 2015-12-01 Fusion proteins and methods for treating, preventing or ameliorating pain
HK18105260.2A HK1245833B (zh) 2012-08-27 2018-04-23 用於治療、預防或緩解疼痛的融合蛋白和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18105260.2A HK1245833B (zh) 2012-08-27 2018-04-23 用於治療、預防或緩解疼痛的融合蛋白和方法

Country Status (18)

Country Link
US (3) US20140056870A1 (xx)
EP (2) EP2888359B1 (xx)
JP (2) JP2015528461A (xx)
KR (1) KR102283218B1 (xx)
CN (1) CN104769108A (xx)
AU (1) AU2013308233B2 (xx)
BR (1) BR112015003947A8 (xx)
CA (1) CA2882233A1 (xx)
DK (1) DK2888359T3 (xx)
ES (2) ES2737850T3 (xx)
HK (2) HK1211056A1 (xx)
HU (1) HUE035286T2 (xx)
MX (1) MX369005B (xx)
PL (1) PL2888359T3 (xx)
PT (1) PT2888359T (xx)
RU (1) RU2652954C2 (xx)
UA (1) UA117349C2 (xx)
WO (1) WO2014033441A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8778634B2 (en) * 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
CN108350039A (zh) 2015-08-27 2018-07-31 哈佛大学校长及研究员协会 用于治疗疼痛的组合物和方法
JP7098519B2 (ja) * 2015-10-08 2022-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ Ｃ型肝炎ウイルスｅ１／ｅ２ヘテロダイマー及びそれを生成する方法
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
CN109790204A (zh) 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US12162912B2 (en) 2018-11-21 2024-12-10 The Regents Of The University Of Colorado, A Body Corporate Proteins for blocking neurotransmitter release
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU7566396A (en) 1995-11-16 1997-06-05 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
IL139478A0 (en) 1998-05-13 2001-11-25 Biotecon Ges Fur Biotechnologi Hybrid protein
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP1700918B1 (en) 1999-08-25 2014-01-15 Allergan, Inc. Activatable recombinant neurotoxins
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
WO2001058936A2 (en) 1999-12-02 2001-08-16 Microbiological Research Authority Constructs for delivery of therapeutic agents to neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
EP1365800B1 (en) 2000-06-28 2013-03-06 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
CN1488000A (zh) * 2001-02-23 2004-04-07 比奥维特罗姆股份公司 纯化可溶性ssao的方法
WO2003030828A2 (en) 2001-10-09 2003-04-17 Synvax, Inc. Nociceptin-based analgesics
AU2003217415B2 (en) * 2002-02-14 2009-01-08 William J Rutter Chimeric molecules for cleavage in a treated host
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
ITMI20022022A1 (it) 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
JP5089388B2 (ja) 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド 分解可能なクロストリジウム毒素
CA2588758C (en) 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
PL1830872T3 (pl) * 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
EP2913056A1 (en) * 2006-01-05 2015-09-02 The University of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
EP2038299A2 (en) * 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
AU2008278970A1 (en) * 2007-07-26 2009-01-29 Tibotec Pharmaceuticals Native gp41 assay
WO2009033733A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of apeptide as a therapeutic agent
WO2009055350A1 (en) 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
NZ585108A (en) 2007-10-23 2012-09-28 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
EP2291399B1 (en) * 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
US8492109B2 (en) 2009-01-20 2013-07-23 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
PL3281953T3 (pl) * 2009-03-13 2020-05-18 Allergan, Inc. Oparte na reakcji immunologicznej testy aktywności przekierowanej endopeptydazy
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303789A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
EP2576625B1 (en) * 2010-06-04 2018-04-25 TiumBio Co., Ltd. Fusion protein having factor vii activity
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins

Also Published As

Publication number Publication date
ES2737850T3 (es) 2020-01-16
US20190309277A1 (en) 2019-10-10
CA2882233A1 (en) 2014-03-06
EP3246405B1 (en) 2019-04-24
MX369005B (es) 2019-10-24
HK1245833B (zh) 2020-02-21
RU2015111001A (ru) 2016-10-20
EP2888359A1 (en) 2015-07-01
UA117349C2 (uk) 2018-07-25
EP2888359B1 (en) 2017-04-12
RU2652954C2 (ru) 2018-05-03
JP2019004909A (ja) 2019-01-17
DK2888359T3 (en) 2017-07-10
CN104769108A (zh) 2015-07-08
AU2013308233A1 (en) 2015-02-26
AU2013308233B2 (en) 2019-05-16
US20150197739A1 (en) 2015-07-16
EP3246405A1 (en) 2017-11-22
JP2015528461A (ja) 2015-09-28
BR112015003947A8 (pt) 2018-05-22
US20140056870A1 (en) 2014-02-27
HUE035286T2 (en) 2018-05-02
WO2014033441A1 (en) 2014-03-06
BR112015003947A2 (pt) 2017-08-08
PL2888359T3 (pl) 2017-09-29
KR102283218B1 (ko) 2021-07-30
MX2015002588A (es) 2015-09-29
PT2888359T (pt) 2017-07-14
US11248219B2 (en) 2022-02-15
KR20150068353A (ko) 2015-06-19
ES2632470T3 (es) 2017-09-13

Similar Documents

Publication Publication Date Title
HK1245833B (zh) 用於治療、預防或緩解疼痛的融合蛋白和方法
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
HK1215378A1 (zh) 藥物組合物、治療方法及其用途
HK1205969A1 (en) Medical microelectrode, method for its manufacture, and use thereof
HK1212186A1 (en) Systems and methods for creating curved paths through bone and modulating nerves within the bone
IL238241A0 (en) Systems and methods for treating a smooth joint surface
EP2906143A4 (en) SYSTEM AND METHOD FOR CARDIAC TREATMENT
GB2520207B8 (en) Authentication method and system
IL238945A0 (en) System and method for optogenetic therapy
HK1248082A1 (zh) 用於接合組織的裝置、系統和方法
SG10201800720YA (en) Blood treatment systems and methods
EP2830702A4 (en) NEUROMODULATION SYSTEM AND RELATED METHODS
EP2833971A4 (en) METHOD, SYSTEM AND USE OF THERAPEUTIC ULTRASOUND
EP2858719A4 (en) Systems and methods for tissue treatment
IL222382A0 (en) Robo1-fc fusion protein and use thereof for treating tumours
EP2884923A4 (en) VERTEBRAL IMPLANT SYSTEM AND METHOD THEREOF
EP2895686A4 (en) DEVICE, METHOD AND SYSTEM FOR TREATING WELLS
EP2836267A4 (en) TREATMENT SYSTEM AND METHOD FOR PATHOLOGICAL ELECTROMAGNETIC LESIONS
EP2793746A4 (en) MEDICAL DEVICE, METHOD AND SYSTEM THEREOF
HK1184867A1 (en) Method and system for user authentication
HK1208598A1 (en) Methods and compositions for treating pain
GB201205911D0 (en) Hair treatment method
IL239654B (en) Process for the preparation of 6alpha, 14alpha-ethanomorphinans from 7-beta mutants and 6alpha, 14alpha-ethanomorphinans from 7-beta mutants
IL238331A0 (en) A method for treating type I and type II diabetes
GB2504745B (en) Authentication system and method

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210829